The Honest Dose #9

Something I've been sitting with lately: I built PeptideClear as a text-first resource because that's genuinely how I process information. I read. I take notes. I go back and reread. The newsletter format made sense because that's how my brain works and, for a while, I assumed it was how most people's brains worked too.

It isn't.

The research on how people actually consume health information is pretty humbling. A large portion of the people who would genuinely benefit from evidence-graded content on peptides will never read a newsletter, and that's not a failing on their part. They're scrolling. They process visually. A 60-second video with a clean hook lands differently than three paragraphs of nuance, even if the three paragraphs are better.

So I'm doing something about that. PeptideClear is now on X (@peptideclear) and Instagram (@peptideclear). Short-form video is next. The format I'm planning maps almost directly to the Claim vs Reality section you're already reading -- take a popular belief, put the research behind it on screen, give you the honest version in under a minute, and point you here for the full breakdown. Same evidence, different surface. I'd rather this work meet people where they are than stay stuck in a format only some of them use.

If you're on those platforms and you see something worth sharing, that's genuinely the most useful thing you can do to help. Thanks for being here regardless of how you got here.

Let's get into it.

GHK-Cu is a copper peptide -- specifically, a tripeptide (three amino acids: glycine, histidine, and lysine) bound to a copper ion. It occurs naturally in human plasma, saliva, and urine, and its levels decline measurably with age. That's not a marketing claim; it's a documented biological fact, and it's part of why the compound has attracted serious research attention for decades.

The core interest in GHK-Cu is its apparent role in tissue repair and skin remodeling. The compound shows up in wound environments in higher concentrations than in normal tissue, which pointed researchers toward its possible function as a biological signal -- something the body uses to coordinate healing responses. That mechanism hypothesis is what launched several decades of lab and clinical investigation.

It's worth noting upfront that GHK-Cu exists across two very different contexts. As Copper Tripeptide-1, it's a legal, widely available cosmetic ingredient found in hundreds of skincare serums. As a compounded injectable, it lives in a more ambiguous regulatory space. Both contexts share the same underlying compound. They don't share the same evidence base.

GHK-Cu has one of the more interesting research profiles in the catalog -- not because the evidence is strong across the board, but because it's genuinely uneven in a way that rewards a closer look.

The clearest findings are in wound healing. A 2021 randomized controlled trial in diabetic ulcer patients found meaningfully better wound closure rates in the GHK-Cu treatment group versus controls, with the effect size substantial enough to be clinically notable. A 2023 Phase II trial in post-surgical patients found reduced scar volume at three months versus standard care, with histological data showing increased fibroblast activity. These are real, controlled findings in humans, not cell cultures, and they're the compound's strongest evidence.

Skin aging is where it gets more complicated. A 2025 meta-analysis pooled seven RCTs and reported a statistically significant effect on wrinkle reduction -- but with high heterogeneity, meaning the results varied considerably across studies. Industry funding appears in a meaningful fraction of the trial literature, which is the kind of conflict that belongs in the RQS methodology and affects the Funding Independence dimension. A 2022 double-blind study found improvements in fine lines and hydration at eight weeks. The topical skin data is genuinely promising but not yet at the level where you'd call it settled.

Hair applications represent the thinnest part of the portfolio. A 2022 RCT found GHK-Cu serum increased hair count in androgenetic alopecia patients at 16 weeks, comparing favorably to a control group. A 2024 study in isolated follicles found interesting molecular activity. But as of a 2025 review, only three RCTs exist on the hair application -- not enough to draw firm conclusions.

The most expansive claims about GHK-Cu -- that it "resets" gene expression across thousands of pathways, that it functions as a systemic anti-aging agent -- come primarily from a prolific researcher, Loren Pickart, who discovered the compound and has spent decades building the case for its broad biological significance. The gene expression data is real and peer-reviewed. The leap from "modulates gene expression" to "systemic rejuvenation" is the kind of gap that deserves to stay a gap until larger human trials validate the direction.

GHK-Cu is a naturally occurring compound with a genuine research history, real wound healing data in humans, and a topical skin evidence base that's promising but inconsistent. The injectable applications -- where most of the wellness-community interest sits -- run considerably ahead of the human evidence. The compound's best-supported use case (wound healing) is also its least discussed in peptide communities, while its most discussed use case (systemic anti-aging) has the thinnest evidence. That gap between what the research supports and what the community emphasizes is the whole reason the RQS exists.

RQS: 55/100 - Limited Evidence

Read the full GHK-Cu profile

The claim: When you're nauseous, reach for ginger ale. It's what your parents gave you. It's what the flight attendant hands you. It's so embedded as the stomach-problem default that it barely registers as a choice anymore.

I believed this. Not as something I'd thought through, as something I'd just absorbed. Then I looked it up.

The reality: Most commercial ginger ale is, chemically speaking, a soda. Carbonated water, high-fructose corn syrup, and ginger flavoring, which is not the same thing as ginger. The active compounds in ginger that actually do something in the body are gingerols and shogaols. In standard commercial ginger ale, these are present in amounts too small to produce a clinical effect. A gastroenterologist cited in a 2025 review put it plainly: there is no clinical evidence supporting ginger ale's effectiveness as a stomach remedy, and the carbonation and sugar content can actually worsen bloating and reflux symptoms in some people.

Here's the legitimately interesting part: ginger itself, as a botanical compound, does have a real evidence base for nausea. A 2022 systematic review covering 23 randomized controlled trials found that ginger supplementation showed meaningful effects on delayed chemotherapy-induced nausea and vomiting. Meta-analyses support its use in pregnancy-related nausea. The mechanism is plausible, gingerols appear to act on serotonin receptors involved in nausea signaling. The American College of Gastroenterology has included ginger in clinical guidelines for specific nausea contexts.

The problem isn't ginger. The problem is that ginger ale mostly doesn't have enough of it to matter.

The reason ginger ale carries this reputation at all is historical. Earlier versions of the drink actually contained real ginger root and were marketed as digestive tonics. The formula changed; the reputation didn't. What's left is the placebo effect of something warm and fizzy that you associate with being cared for, which is a real phenomenon, just not a pharmacological one.

The honest version of the claim: Ginger works for certain kinds of nausea. Ginger ale, as most commercial brands make it, is not a meaningful delivery vehicle for ginger. If you want the actual compound, you need actual ginger, fresh root, standardized capsules, or ginger tea made with real dried rhizome. The difference between the thing that works and the thing you've been reaching for is mostly marketing and decades of habit.

GHK-Cu at 55 sits in the middle of the Limited Evidence band, and it's worth explaining why the score lands there rather than higher, because on first read, the compound's history looks more impressive than a 55 suggests.

The Study Design dimension is where GHK-Cu genuinely earns points. The wound healing literature has actual randomized controlled trials with control groups, histological data, and clinical endpoints. That's meaningfully better design than most compounds in the 40s and low 50s, which are often surviving on open-label pilot work or animal models. On study quality alone, GHK-Cu would score higher.

The problem is the Funding Independence dimension. A notable fraction of the skin aging trial literature carries industry involvement, and the primary researcher most associated with expanding GHK-Cu's theoretical scope is the same person who holds commercial interests in the compound's applications. The RQS methodology accounts for this the same way it did with BPC-157, not by assuming the research is wrong, but by registering that financial entanglement is a documented source of publication bias, and that scoring requires accounting for it. Funding conflicts don't invalidate findings; they adjust the confidence we should place in them.

The Replication dimension does additional work limiting the score. The skin aging evidence, while growing, shows high variability across studies. The hair evidence is three RCTs. The gene expression literature, though prolific, is largely in vitro and animal work. None of these add up to replication at the level that would push the score into Moderate territory.

What you're left with is a compound that has the best evidence where the wellness community focuses least (wound healing) and the weakest evidence where the community focuses most (systemic anti-aging). The 55 reflects the whole picture, not just the strongest corner of it.

The FDA's PCAC meeting on peptides is happening in two weeks. The Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24, 2026, to evaluate seven peptides for potential inclusion on the 503A Bulk Drug Substances list: BPC-157, KPV, TB-500, MOTs-C, DSIP (which I covered last issue), Semax, and Epitalon. Inclusion on this list would mean compounding pharmacies could legally prepare these substances under prescription -- a meaningful shift from the current gray-market situation. The important framing: PCAC's recommendation is non-binding, and formal rulemaking would still be required after any recommendation, a process that typically takes a year or more. Even if the committee recommends inclusion, don't expect the access landscape to change overnight. This is a procedural step, not a green light. NPR reported this week that the FDA's own scientists have come out against lifting restrictions on any of the seven peptides, citing unclear benefit-to-risk profiles -- which sets up a meaningful tension between the agency's scientific staff and the external committee it convened. I'll continue following this and will report back when the meeting produces something concrete.

The mainstream peptide conversation is catching up to the evidence problem. CNN, Forbes Health, and NPR all published long-form pieces on the peptide space in the past three months, and the through-line across all three is the same thing PeptideClear has been saying since Issue #1: the gap between community enthusiasm and controlled human evidence is wide, and the compounds generating the most hype often have the thinnest clinical data. CNN quoted a physician noting that the peptide market is moving from unregulated gray area toward more structured oversight. That's the direction this is all heading, and the evidence-literacy infrastructure has to exist before access opens wider -- not after. This newsletter exists for exactly that reason.

GHK-Cu is being mentioned in the same sentence as compounded peptide therapy, and that framing deserves scrutiny. The same CNN piece quoted a physician who uses GHK-Cu alongside BPC-157 in post-surgical recovery. That's a real clinical context with some evidence behind it. What gets blurry is when the wound-healing data gets borrowed to support systemic wellness claims for GHK-Cu that the research hasn't actually tested. Worth holding the distinction: a compound with real evidence for one application doesn't automatically carry that evidence to different applications. The RQS scores the research that exists, not the research people wish existed.

Staying in the skin peptide world that GHK-Cu occupies, Argireline (also known by its chemical name acetyl hexapeptide-3), is a useful companion compound because it targets the same general category (visible aging) through an entirely different mechanism and with a strikingly different evidence story.

Where GHK-Cu works by promoting tissue repair and collagen synthesis, Argireline is sometimes called "topical botox" because it targets the same pathway as the neurotoxin, inhibiting the release of neurotransmitters that cause facial muscle contractions, which produce wrinkles. The marketing pitch is that you can get Botox-adjacent effects from a serum. That's the claim. Here's where it gets complicated.

Argireline's mechanism is real and biochemically plausible. In vitro studies confirm it does interfere with the relevant neurotransmitter signaling. The issue is that the human skin is not a petri dish. Getting a large peptide molecule to penetrate the skin barrier at sufficient concentrations to produce a meaningful neuromuscular effect on underlying muscle tissue is a formulation and delivery challenge that the existing trial literature hasn't convincingly solved. The human RCT data for Argireline is small, short in duration, and often funded by suppliers of the ingredient. Effects on wrinkle appearance have been reported but are modest and inconsistent.

It's a compound where the mechanism sounds compelling and the evidence doesn't yet match the pitch. The skin peptide world has a lot of those, and being honest about the gap is what keeps this catalog useful.

RQS: 48/100 - Limited Evidence

Read the full Argireline profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.